January 24, 2014 16:30 ET
WINNIPEG, MANITOBA--(Marketwired - Jan. 24, 2014) - Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares") on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu® POC Test is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. The Company's Scout DS® system is the first non-invasive diabetes testing system designed to provide a highly sensitive and convenient method for measuring diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. The Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies. For more information visit www.miraculins.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
PreVu® and SCOUT DS® are registered trademarks of Miraculins Inc. All Rights Reserved. 2014.
Miraculins Inc.Christopher J. MoreauPresident & CEO204-477-7599204-453-1546 (FAX)firstname.lastname@example.org
See all RSS Newsfeeds